HYPOXIA-INDUCIBLE FACTOR AS A MOLECULAR TARGET IN HEPATORENAL SYNDROME

被引:0
|
作者
Virstyuk, N. G. [1 ]
Slyvka, N. A. [2 ]
机构
[1] Ivano Frankivsk Natl State Med Univ, Int Ukrainian Univ, Ivano Frankivsk, Ukraine
[2] Bukovinian State Med Univ, Inst Internal Affairs Ukraine, Chernovtsy, Ukraine
来源
WORLD OF MEDICINE AND BIOLOGY | 2018年 / 65卷 / 03期
关键词
hepatorenal syndrome (HRS); alcoholic liver cirrhosis (ALC); hypoxia-inducible factor; hepatic renal failure;
D O I
10.26724/2079-8334-2018-3-65-23-28
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Hepatorenal syndrome (HRS) is a serious complication of alcohol liver cirrhosis (ALC). Studying of the mechanisms of molecular response to hypoxia in HRS is a promising direction of research in hepatology. The aim of present study was to evaluate the role of hypoxia-inducible factor HIF-1 alpha in the pathogenesis of HRS at the acute-on-chronic (ACLF) liver failure (CLF) in patients with ALC. 150 patients with ALC+ HRS were divided into 2 groups: I group (n= 67) -CLF,II group(n= 83) - ACLF. Level of HIF-1 alpha in the most severe category of patients in group 2, with stage IV by CLIF-C-ACLF scale, was almost three times higher than that of a similar category in group 1, with Child-Pugh C class, and was 30 +/- 7,9 ng/ml. Dramatic increase of HIF-1a level in the group 2 patients with the IV stage by CLIF-C-ACLF scale confirms the severe tissue hypoxia, which is caused by a significant deterioration of the splanchnic blood flow and spasm of renal vessels at the HRS. HIF-1 alpha levels closely correlate with the indicators of hepatic and renal failure in the patients with ALC+HRS, which allows to use it as an indicator for comprehensive diagnosis of this disease.
引用
收藏
页码:23 / 28
页数:7
相关论文
共 50 条
  • [41] Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling
    Haenze, Joerg
    Weissmann, Norbert
    Grimminger, Friedrich
    Seeger, Werner
    Rose, Frank
    THROMBOSIS AND HAEMOSTASIS, 2007, 97 (05) : 774 - 787
  • [42] Hypoxia-Inducible Factor and Oxidative Stress in Tendon Degeneration: A Molecular Perspective
    Shahid, Hamzah
    Morya, Vivek Kumar
    Oh, Ji-Ung
    Kim, Jae-Hyung
    Noh, Kyu-Cheol
    ANTIOXIDANTS, 2024, 13 (01)
  • [43] Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria
    Luke W. Thomas
    Margaret Ashcroft
    Cellular and Molecular Life Sciences, 2019, 76 : 1759 - 1777
  • [44] Hypoxia-inducible factor-1: a promising therapeutic target for autoimmune diseases
    Guan, Shi-Yang
    Leng, Rui-Xue
    Tao, Jin-Hui
    Li, Xiang-Pei
    Ye, Dong-Qing
    Olsen, Nancy
    Zheng, Song Guo
    Pan, Hai-Feng
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (07) : 715 - 723
  • [45] Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
    Kasivisvanathan, Veeru
    Shalhoub, Joseph
    Lim, Chung S.
    Shepherd, Amanda C.
    Thapar, Ankur
    Davies, Alun H.
    CURRENT VASCULAR PHARMACOLOGY, 2011, 9 (03) : 333 - 349
  • [46] Hypoxia-Inducible Factor-2α as a Novel Target in Renal Cell Carcinoma
    Choi, Won Seok W.
    Boland, Julia
    Lin, Jianqing
    JOURNAL OF KIDNEY CANCER AND VHL, 2021, 8 (02): : 1 - 7
  • [47] Copper manipulation of target gene selectivity of hypoxia-inducible factor-1
    Zhang, Wenjing
    Liu, Xiaojuan
    Wu, Zhijuan
    Kang, Y. James
    FASEB JOURNAL, 2017, 31
  • [48] Hypoxia-Inducible Factor-1 as a Therapeutic Target in Endometrial Cancer Management
    Seeber, Laura M. S.
    Zweemer, Ronald P.
    Verheijen, Rene H. M.
    van Diest, Paul J.
    OBSTETRICS AND GYNECOLOGY INTERNATIONAL, 2010, 2010
  • [49] Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy
    Clottes, T
    BULLETIN DU CANCER, 2005, 92 (02) : 119 - 127
  • [50] Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria
    Thomas, Luke W.
    Ashcroft, Margaret
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2019, 76 (09) : 1759 - 1777